



Contact information:

Meghan Morrissey

PharmaVigilant

(508) 475-4222

mmorrissey@pharmavigilant.com

PHARMAVIGILANT FOUNDER, CEO TO SPEAK AT DIA 2012 48th ANNUAL MEETING

James DeSanti to Present on the Benefits of Centralized Monitoring as well as Medical Imaging.

WESTBOROUGH, Mass., June 21, 2012 – PharmaVigilant, an e-clinical provider, announced today that James DeSanti, Founder and CEO of PharmaVigilant, will speak on two separate occasions at the [DIA 2012 48th Annual Meeting](#) to be held June 24-28 at the Pennsylvania Convention Center.

With more than 20 years of experience in the bio/pharmaceutical industry, DeSanti has been recognized for being an innovator in clinical research technology. On Monday, June 25th at 1:30pm, he will share his expertise in the symposium entitled ["Capitalizing on Biometric Efficiencies: A Look at Data Start-up, Capture, Monitoring, and Reporting."](#) During his presentation he will discuss the implementation, benefits, and results of instituting centralized monitoring in your clinical trial.

Tuesday, June 26th at 8am, DeSanti will present again in the symposium entitled ["Evolving eContent Design and Exchange for Clinical Studies."](#) He will discuss the benefits of using an eTMF system that allows for the integration of medical imaging in your clinical trials, with supporting metrics from a case study in the musculoskeletal therapeutic area.

Those interested in learning more about DeSanti's presentations, or how PharmaVigilant's suite of e-clinical software and services can assist you in the second half of 2012 and beyond, please visit us at booth number 3111. If you are not attending



the DIA but would like to hear more about our experience, please call us at 508-898-0018.

About PharmaVigilant:

Based in Westborough, Mass., PharmaVigilant is a SaaS company founded to provide broader Solutions to streamline the clinical trial process for biopharmaceutical companies. Its full suite of SaaS solutions automates the collection, management and analysis of clinical trial data. For more information, visit www.pharmavigilant.com

ABOUT DIA

DIA is a neutral, global, member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology and medical devices. Through international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China. Follow DIA on FaceBook, Twitter, LinkedIn and YouTube.